{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:17:08Z","timestamp":1770049028195,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The majority of tumors in the upper urinary tract are classified as urothelial carcinomas, with only 15% exhibiting different levels of squamous differentiation, known as the squamous subtype. These tumors tend to be more aggressive and are associated with a worse prognosis compared to standard urothelial carcinomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 60-year-old man was found to have cancer in his left ureter and subsequently underwent a robot-assisted laparoscopic procedure to partially remove the left ureter and perform a ureterovesical anastomosis. The postoperative analysis revealed high-grade urothelial carcinoma with marked squamous differentiation(40% squamous differentiation) and microsatellite stability (MSS). Three months after surgery, the abdominal incision recurred and abdominal mass resection was performed again. One month after abdominal surgery, imaging evaluation showed lymph node metastasis in the left lower wall of the bladder and retroperitoneum.Ultimately, the patient attained complete imaging remission following treatment with the \\GC\\ chemotherapy regimen, along with \\tislelizumab\\ immunotherapy and radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The \\GC\\ chemotherapy protocol, along with \\tislelizumab\\ immunotherapy and radiotherapy, shows remarkable effectiveness in treating metastatic ureteral urothelial carcinoma with significant squamous differentiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1702896","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:16:23Z","timestamp":1770009383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Chemotherapy, immunotherapy, and radiotherapy achieve complete response for metastatic ureteral urothelial carcinoma with significant squamous differentiation"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShangHu","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChongJian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","article-title":"Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma","volume":"8","author":"Makise","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.07.364","article-title":"Risk factors and predictive value of local recurrence in chinese upper tract urothelial carcinoma patients: implication for postoperative adjuvant radiation therapy","volume":"102","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e002552","DOI":"10.1136\/jitc-2021-002552","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","volume":"9","author":"Galsky","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.047","article-title":"Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications","volume":"74","author":"Hovelson","year":"2018","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.10.005","article-title":"Patient characteristics, treatment patterns and prognostic factors in squamous cell bladder cancer","volume":"16","author":"Zahoor","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B11","article-title":"Expert group of standardized laparoscopic radical nephroureterectomy","volume":"9","year":"2020","journal-title":"J Minimally Invasive Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000133","article-title":"Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy","volume":"4","author":"Sigurdsson","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6807","article-title":"The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single-center study based on propensity score matching","volume":"12","author":"Gao","year":"2023","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.08.003","article-title":"French AFU Cancer Committee Guidelines - Update 2022-2024: Upper urinary tract urothelial cancer (UTUC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001264","article-title":"PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies","volume":"43","author":"Reis","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09900.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1390-6","article-title":"Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer","volume":"62","author":"Ramakrishnan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-4992.2017.08.042","article-title":"Development status and prospects of tumor radiotherapy combined with immunotherapy","volume":"25","author":"Liu","year":"2017","journal-title":"J Modern Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03659-2","article-title":"Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study","volume":"27","author":"Quan","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.tps718","article-title":"WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma\u2014A phase II multi-center study","volume":"42","author":"Bao","year":"2025","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.591","article-title":"A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC)","volume":"42","author":"Huang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13014-022-02020-7","article-title":"Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy","volume":"17","author":"Kim","year":"2022","journal-title":"Radiat Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113030-20220314-00094","article-title":"The roles and clinical controversies of radiotherapy and immunotherapy in abscopal effect","volume":"32","author":"Zhang","year":"2023","journal-title":"Chin J Radiat Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mgene.2017.01.002","article-title":"Assessment of p53 mutations, expression and prognosis in bladder cancer patients from Jordan: Identification of novel deletion mutations in the DNA-binding domain","volume":"12","author":"Guo","year":"2025","journal-title":"Meta Gene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"290.e17","DOI":"10.1016\/j.urolonc.2018.12.027","article-title":"Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy","volume":"37","author":"Zeng","year":"2019","journal-title":"Urol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw005","article-title":"Diversity in treatment modalities of Stage II\/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association","volume":"46","author":"Koie","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07988.x","article-title":"Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density","volume":"103","author":"Bolenz","year":"2009","journal-title":"BJU Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.11.058","article-title":"The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience","volume":"79","author":"Mason","year":"2012","journal-title":"Urology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081190","article-title":"Lymphadenectomy for upper tract urothelial carcinoma: A systematic review","volume":"8","author":"Duquesne","year":"2019","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1702896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:16:25Z","timestamp":1770009385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1702896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1702896"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1702896","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1702896"}}